We look forward to seeing you.
Schedule an Appointment: 775-825-1586
In a world where beauty standards are constantly evolving, the demand for effective anti-aging solutions has never been greater. While Botox injections have long been a popular choice for those seeking a youthful appearance, there is now an innovative and longer-lasting alternative that is taking the beauty industry by storm – Daxxify.
Daxxify may look like Botox, and work like Botox, but it’s different from Botox (in a good way!). Part of a group of medications called neuromodulators, which include the more famous relatives – Botox, Dysport, Xeomin, and Jeuveau, Daxxify joins the fight against facial wrinkles and aging.
This frown line treatment distinguishes itself by being devoid of human serum albumin, a protein present in human blood and animal-derived components. Daxxify employs a peptide exchange technology, distinct from Botox’s utilization of human serum albumin, to deliver the toxin to the nerve cells. The proprietary stabilizing protein enhances the interaction between the treatment and its targeted areas, resulting in longer-lasting outcomes.
According to the American Society for Dermatologic Surgery (ASDS), the more popular neuromodulators, such as Botox and Dysport, typically have effects that last approximately three months. What sets Daxxify apart is its potential to extend the wrinkle-reducing effects for a longer duration. In clinical trials submitted to the FDA for approval, it was observed that 80 percent of individuals using Daxxify had either no wrinkles or very minimal wrinkles after four months. Additionally, around half of the participants still showed little signs of wrinkles even after six months.
Daxxify, also known as Daxi (daxibotulinumtoxinA-lanm), represents an innovative alternative to Botox, purposefully designed to address and mitigate the appearance of wrinkles, particularly severe frown lines and glabellar lines.
Daxxify stands as a pioneering and exclusive wrinkle-relaxing injectable treatment in the market, being the first and presently the sole peptide-formulated option of its kind. Functioning akin to Botox, Daxxify operates by immobilizing and smoothing facial lines and wrinkles through the temporary paralysis of underlying muscles using small quantities of toxin. This mechanism induces relaxation in the facial muscles and connective tissues, leading to a rejuvenated and smoother appearance of the skin.
As the first and only peptide-formulated neuromodulator, this cosmetic treatment allows for the successful integration of peptides in topical, oral, and injectable products. Extensive studies conducted on Daxxify reveal its safety and efficacy as a neuromodulator that effectively slows down the accelerated aging caused by moderate to severe muscle movements.
Furthermore, due to its stability at room temperature, there is no need for refrigeration as is the case with Botox. Daxxify demonstrates a prompt onset of results, with noticeable improvements possible as early as one day following treatment, in contrast to certain other neuromodulators that may require a longer duration to take effect.
Daxxify is FDA-approved only to smooth frown lines, whereas botulinum toxin injections are also approved to treat other parts of the face, such as crow’s-feet. Furthermore, unlike the botulinum toxin type A which is FDA-approved for a wide variety of uses, including to treat migraines, overactive bladder, and hyperhidrosis, Daxxify works best for horizontal forehead lines.
Opting for Daxxify as a potential treatment choice for facial lines and severe wrinkles may be particularly suitable for individuals who have previously undergone another injectable procedure or botulinum toxin products. This is primarily due to the significantly extended duration of results offered by Daxxify, which can be up to twice as long as other neuromodulators like Botox. The notable aspect of this prolonged effect is that it limits the ability to reverse any outcome that may not meet one’s expectations.
The side effects associated with Daxxify closely resemble those observed with botulinum toxin products. These common side effects include headache, localized reactions at the injection site such as pain, swelling, itching, bruising, or redness, as well as facial swelling and numbness. In rare instances, individuals may experience eyelid ptosis, commonly referred to as drooping eyelids, which represents a more severe manifestation. It is important to note that while these side effects can occur, they are typically temporary and resolve on their own.
During clinical trials conducted by Revance, no significant treatment-related adverse effects were observed. According to their findings, the most frequently reported side effect among users was a headache, reported by 6 percent of participants. Additionally, a small percentage of users, specifically 2 percent, experienced temporary drooping eyelids, while facial asymmetry was reported by 1 percent of users. These observations suggest that Daxxify exhibits a favorable safety profile with a low incidence of adverse effects during the clinical trial phase.
Aesthetics MedSpa is among the first medical spas to offer access to Daxxify treatments administered by a team of highly skilled skincare experts who have undergone specialized training in this innovative procedure. With their extensive knowledge and expertise, our professionals ensure the highest standard of care and precision when performing Daxxify injections. By choosing our medical spa, you can confidently embark on your journey to achieve your aesthetic goals. Experience the transformative power of Daxxify under the care of our skilled skincare experts at our premier medical spa.
Aesthetics MedSpa is considered the best medical spa in Reno, Nevada! But don’t take our word for it. We’ve been named Reno’s Best Medical Spa 13 years running and were recently inducted into the Reno Business Hall of Fame. Check out all of our awards and recognitions as well as our raving customer reviews to learn why we’re Reno’s best Medspa.
6295 Sharland Avenue, Suite 1
Reno, NV 89523